Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-Dose IL-2 in Alzheimer's Disease
NCT05821153Phase 1Completed
- Sponsor
- Houston Methodist Research Institute
- Start
- Jun 2019
- Primary completion
- Apr 2022
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of aldesleukin in Alzheimer's disease (AD), sponsored by Houston Methodist Research Institute. Primary endpoint: Safety and tolerability of IL-2 in AD patients at 4 months. Started Jun 2019; status: completed.
02
Drugs
aldesleukin
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05821153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05821153.